LIVERMORE, Calif., Feb. 11, 2012 /PRNewswire/ – Halt Medical, Inc. announced today that it has closed on the first $20 million of a planned $50 million debt and equity financing.
“Leading the financing with the first $20 million is our long term investment partner American Capital Strategies (ACAS). American Capital’s financial resources, global perspective and life science expertise has made them the perfect financing partner for Halt Medical. Following the lead of American Capital, other investors are climbing on board. We will be closing on another $10 million this quarter with the option for an additional $20 million,” said Jeff Cohen, Halt Medical CEO.
Cohen added, “With fibroid approvals in Canada and Europe and expected soon in the U.S., it’s time to focus our attention on building out our commercial organization. $50 million in fresh capital will enable us to launch the Halt Global Fibroid Ablation (GFA) System in major markets around the world.”
Russ DeLonzor, President & COO added, “While many competitive products targeting uterine fibroids have been rejected by the medical community and regulators, we are seeing an overwhelming interest in Halt Medical’s GFA product. This round of fundraising will be put to immediate use in building up the infrastructure required for us to meet one of the biggest unmet needs in women’s health worldwide.”
About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device company focused on women’s health. The company has developed a procedure and related equipment for treating uterine fibroids that is less expensive, more effective and less invasive than other alternatives – the Halt GFA System. In June 2010, the U.S. Food and Drug Administration cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy. The results of Halt Medical’s international studies have led to recent approvals for treating uterine fibroids in Canada and the European Union. The Halt System may be used for general surgical use in the U.S. The company recently completed a 137 patient IDE clinical trial at 11 sites in 3 countries to demonstrate clinical safety and efficacy in the treatment of symptomatic uterine fibroids. FDA clearance is expected this year. The Company is located in Livermore, CA.
Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at www.clinicaltrials.gov, study number NCT00874029.
http://tourism9.com/ http://vkins.com/
2012年2月10日星期五
Concord-Based SpaceClaim Claims $4M – cbl
More Topics:
Posted February 9, 2012
Chris RandlesBy Richard Rabicoff
CONCORD — Space Claim Corp., a 3D modeling company, completed a $4 million equity offering, with 12 investors participating.
Earlier this week, the company announced that it completed a Series D financing of $11 million, to fund investment in R&D and expansion of global sales channels. Investors included North Bridge Venture Partners, Kodiak Venture Partners, Borealis Ventures, and Needham Capital. Those investors had earlier poured about $19 million in SpaceClaim.
Named in the related SEC filing are president and CEO Chris Randles, CFO and vice president of Finance and Operations Gregory Stott, and directors Richard D’Amore from Waltham-based North Bridge Venture Partners; Richard Riff from Ford Motor Company; Lou Volpe from Waltham-based Kodiak Venture Partners; Michael Payne, SpaceClaim founder; Jesse Devitte from Hanover, N.H.-based Borealis Ventures; and Bharatan Patel from Lebanon, N.H.-based Fluent Inc.
Randles was most recently Entrepreneur-in-Residence at Borealis Ventures. Prior to Borealis, he led the management buyout of Mathsoft and served as its chairman, president and CEO until the company was acquired by PTC (Parametric Technology Corporation). Randles holds Bachelor’s and Master’s degrees from the University of Oxford, England.
Founded in 2005, SpaceClaim creates 3D solid models to enable engineers and industrial designers the ability to capture ideas, directly edit solid models regardless of their origin, and simplify designs in 3D for analysis, prototyping, and manufacturing.
Customers include Toyota Motor Corporation, Nokia Siemens Networks, Bosch, TE Connectivity, BorgWarner, Medtronic, Lotus Cars, Sharp, Ford Motor Company, LG Electronics, Eaton, K2 Medical Systems, FuelCell Energy, Emhart Glass, GE Aviation, Carl Zeiss, General Dynamics, and the U.S. Navy.
The company recently announced that its new license sales increased by more than 110 percent in 2011 and that it has more than doubled its number of resellers.
SEC filing: http://tinyurl.com/7d5kq5w
Also at citybizlist, see:
SpaceClaim Stakes Claim to $7M – cbl
blog comments powered by
http://tourism9.com/ http://vkins.com/
Posted February 9, 2012
Chris RandlesCONCORD — Space Claim Corp., a 3D modeling company, completed a $4 million equity offering, with 12 investors participating.
Earlier this week, the company announced that it completed a Series D financing of $11 million, to fund investment in R&D and expansion of global sales channels. Investors included North Bridge Venture Partners, Kodiak Venture Partners, Borealis Ventures, and Needham Capital. Those investors had earlier poured about $19 million in SpaceClaim.
Named in the related SEC filing are president and CEO Chris Randles, CFO and vice president of Finance and Operations Gregory Stott, and directors Richard D’Amore from Waltham-based North Bridge Venture Partners; Richard Riff from Ford Motor Company; Lou Volpe from Waltham-based Kodiak Venture Partners; Michael Payne, SpaceClaim founder; Jesse Devitte from Hanover, N.H.-based Borealis Ventures; and Bharatan Patel from Lebanon, N.H.-based Fluent Inc.
Randles was most recently Entrepreneur-in-Residence at Borealis Ventures. Prior to Borealis, he led the management buyout of Mathsoft and served as its chairman, president and CEO until the company was acquired by PTC (Parametric Technology Corporation). Randles holds Bachelor’s and Master’s degrees from the University of Oxford, England.
Founded in 2005, SpaceClaim creates 3D solid models to enable engineers and industrial designers the ability to capture ideas, directly edit solid models regardless of their origin, and simplify designs in 3D for analysis, prototyping, and manufacturing.
Customers include Toyota Motor Corporation, Nokia Siemens Networks, Bosch, TE Connectivity, BorgWarner, Medtronic, Lotus Cars, Sharp, Ford Motor Company, LG Electronics, Eaton, K2 Medical Systems, FuelCell Energy, Emhart Glass, GE Aviation, Carl Zeiss, General Dynamics, and the U.S. Navy.
The company recently announced that its new license sales increased by more than 110 percent in 2011 and that it has more than doubled its number of resellers.
SEC filing: http://tinyurl.com/7d5kq5w
Also at citybizlist, see:
SpaceClaim Stakes Claim to $7M – cbl
To find out more about the company in this article and to see if you
have business connections, click below:
Please enable JavaScript to view the comments powered by Disqus.have business connections, click below:
blog comments powered by
http://tourism9.com/ http://vkins.com/
2012年2月1日星期三
RegeneRx Engages Investment Bankers to Assist in Evaluating and Exploring Strategic Opportunities
ROCKVILLE, Md.–(BUSINESS WIRE)– RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) has hired investment bankers, Ameritech Advisors, LLC and Aurora Capital, LLC, to help the Company evaluate and explore potential strategic opportunities. Additionally, the Company is continuing to move forward in early-stage discussions with potential strategic partners related to its ophthalmic drug candidate, RGN-259 for the treatment of dry eye, which it had previously announced. During the past few weeks, a number of additional companies have expressed interest in exploring a partnering transaction involving RGN-259 or a broader strategic transaction, and the Company is exploring these opportunities as well.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development and has an extensive worldwide patent portfolio covering its products.
RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications. Based on a recently completed Phase 2 clinical trial in patients with dry eye syndrome, RGN-259 was found to show statistically significant improvements in several signs and symptoms of dry eye, as well as positive trends in other outcome measures. We believe the positive results of this Phase 2 exploratory trial reflect RGN-259’s reported mechanisms of action and provide RegeneRx with FDA-approvable endpoints to be targeted in future clinical trials.
RGN-352 is an injectable formulation to treat cardiovascular and central nervous system diseases, as well as other medical indications. RegeneRx is initially targeting RGN-352 for the treatment of patients who have suffered an acute myocardial infarction, or heart attack. Recent pre-clinical efficacy data suggests that RGN-352 may also benefit patients with multiple sclerosis, stroke and traumatic brain injury. RegeneRx has successfully completed a Phase 1 clinical trial with RGN-352 in which the drug candidate was found to be safe and well-tolerated. In 2010, RegeneRx received a $3 million, three-year development grant from the NIH to support the company’s acute myocardial infarction program.
RGN-137, a topical gel formulation, is currently being evaluated by RegeneRx in a Phase 2 clinical trial for the treatment of the orphan skin disease epidermolysis bullosa. Other potential uses for RGN-137 include the treatment of chronic dermal wounds and reduction of scar tissue. RegeneRx previously received $675,000 in grants from the U.S. FDA to support this clinical trial.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this press release include statements concerning a potential strategic transaction involving the Company, a potential partnering transaction involving RGN-259 and other statements that include the words “believe,” “continue,” ”may,” “potential” or the negative of those words or other similar expressions. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include risks related to uncertainties inherent in our business, including, without limitation the risk that third parties may be unwilling to engage in a strategic transaction on terms that are acceptable to the Company and its stockholders or at all, the risk that potential commercial partners may be unwilling to enter into a strategic partnership with us involving RGN-259 or terms acceptable to us or at all, the risk that the Company may require additional financing in order to continue as a going concern for a sufficient period of time to consummate a strategic transaction or partnering transaction, the risk that our product candidates do not demonstrate safety and/or efficacy in current clinical trials or future non-clinical or clinical trials; risks related to our ability to obtain financing to support our operations on commercially reasonable terms; the progress, timing or success of our clinical trials; difficulties or delays in development, testing, obtaining regulatory approval for producing and marketing our product candidates; regulatory developments; the size and growth potential of the markets for our product candidates and our ability to serve those markets; the scope and validity of patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2010, filed with the SEC on March 31, 2011, and quarterly reports on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
http://tourism9.com/ http://vkins.com/
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development and has an extensive worldwide patent portfolio covering its products.
RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications. Based on a recently completed Phase 2 clinical trial in patients with dry eye syndrome, RGN-259 was found to show statistically significant improvements in several signs and symptoms of dry eye, as well as positive trends in other outcome measures. We believe the positive results of this Phase 2 exploratory trial reflect RGN-259’s reported mechanisms of action and provide RegeneRx with FDA-approvable endpoints to be targeted in future clinical trials.
RGN-352 is an injectable formulation to treat cardiovascular and central nervous system diseases, as well as other medical indications. RegeneRx is initially targeting RGN-352 for the treatment of patients who have suffered an acute myocardial infarction, or heart attack. Recent pre-clinical efficacy data suggests that RGN-352 may also benefit patients with multiple sclerosis, stroke and traumatic brain injury. RegeneRx has successfully completed a Phase 1 clinical trial with RGN-352 in which the drug candidate was found to be safe and well-tolerated. In 2010, RegeneRx received a $3 million, three-year development grant from the NIH to support the company’s acute myocardial infarction program.
RGN-137, a topical gel formulation, is currently being evaluated by RegeneRx in a Phase 2 clinical trial for the treatment of the orphan skin disease epidermolysis bullosa. Other potential uses for RGN-137 include the treatment of chronic dermal wounds and reduction of scar tissue. RegeneRx previously received $675,000 in grants from the U.S. FDA to support this clinical trial.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this press release include statements concerning a potential strategic transaction involving the Company, a potential partnering transaction involving RGN-259 and other statements that include the words “believe,” “continue,” ”may,” “potential” or the negative of those words or other similar expressions. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include risks related to uncertainties inherent in our business, including, without limitation the risk that third parties may be unwilling to engage in a strategic transaction on terms that are acceptable to the Company and its stockholders or at all, the risk that potential commercial partners may be unwilling to enter into a strategic partnership with us involving RGN-259 or terms acceptable to us or at all, the risk that the Company may require additional financing in order to continue as a going concern for a sufficient period of time to consummate a strategic transaction or partnering transaction, the risk that our product candidates do not demonstrate safety and/or efficacy in current clinical trials or future non-clinical or clinical trials; risks related to our ability to obtain financing to support our operations on commercially reasonable terms; the progress, timing or success of our clinical trials; difficulties or delays in development, testing, obtaining regulatory approval for producing and marketing our product candidates; regulatory developments; the size and growth potential of the markets for our product candidates and our ability to serve those markets; the scope and validity of patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2010, filed with the SEC on March 31, 2011, and quarterly reports on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
http://tourism9.com/ http://vkins.com/
CORRECTING and REPLACING Medical Properties Trust in $400 Million Transaction with Ernest Health, Inc. to Add 16 …
BIRMINGHAM, Ala.–(BUSINESS WIRE)– Second and third sentences of the first graph under PORTFOLIO UPDATE AND FUTURE OUTLOOK section should read: Based solely on the portfolio as of December 31, 2011, the Ernest transactions and the related financing transactions, the Company estimates that annualized Normalized FFO per share would approximate $0.88 to $0.92 per diluted share. The Florence Hospital in Arizona, which is expected to open in the first quarter of 2012, will add approximately $0.03 of FFO annually per diluted share, as previously announced.
The corrected release reads:
MEDICAL PROPERTIES TRUST IN $400 MILLION TRANSACTION WITH ERNEST HEALTH, INC. TO ADD 16 HOSPITALS TO PORTFOLIO
FFO Accretion of 26%
Medical Properties Trust, Inc. (NYSE: MPW – News) today announced that it has agreed to a series of transactions with Ernest Health, Inc. that will add 16 existing post acute care hospitals to MPT’s investment portfolio for approximately $300 million. In addition, the Company will acquire a significant percentage of Ernest Health’s operations, in partnership with Ernest Health’s management team. This $400 million transaction increases Medical Properties Trust’s overall assets by 25 percent, to more than $2.0 billion.
Upon completion of the transactions, which is subject to regulatory and other customary conditions, MPT is expected to have investments in 78 hospital facilities in 24 states, total assets of approximately $2.0 billion and no tenant group that represents more than 20% of its total assets. The transactions are expected to add approximately $0.19 per share in funds from operations in the 12 months following the closing, which is anticipated to occur during the first quarter of 2012. Based on MPT’s most recently disclosed expectations of future FFO, the incremental FFO from the Ernest transactions will represent an increase of 26%.
Founded in 2003, Ernest Health, Inc. is one of the nation’s leading operators of long-term acute care hospitals (“LTACHs”) and inpatient rehabilitation hospitals (“IRFs”). Headquartered in Albuquerque, New Mexico, Ernest operates 16 properties (8 LTACHs and 8 IRFs) with 606 beds across nine states. Subsequent to the transactions, Ernest will be managed pursuant to agreements with current executive management, including Darby Brockette, Ernest’s Chief Executive Officer.
“We are delighted to welcome Ernest Health to the MPT family of premier healthcare facilities,” said Edward K Aldag, Jr., chairman, president and CEO of Medical Properties Trust, Inc. “We have known the Ernest management team for a long time and we have watched the company grow from its inception during the same year MPT was founded. We have been very impressed with Ernest’s growth and with the management team’s dedication to the delivery of high quality healthcare.” Aldag continued, “With transformative, highly accretive transactions like these, we continue to demonstrate our unique ability to create high quality long term sources of cash flow from hospital real estate. Completing these transactions will give MPT upside potential to the long term growth of Ernest, and adds another premiere post acute hospital operator to our relationships with others such as Vibra, Kindred, Healthsouth, LifeCare, Cornerstone and Post Acute.”
Among other benchmarks of quality, Aldag noted that Ernest Health’s inpatient rehabilitation facilities have been ranked among the top five percent of more than 800 IRFs in the United States – and that has held true of each Ernest rehabilitation hospital during each year of its operations. “This commitment to outstanding patient outcomes is only one of the many factors that make the acquisition of Ernest Health so attractive,” Aldag said.
Transaction Details
MPT will acquire the real estate assets of 12 Ernest facilities for an aggregate purchase price of $200 million, and lease the properties back to Ernest under a master lease structure with an initial term of 20 years and three five-year extension options. The real estate of four other Ernest facilities will serve as first lien collateral under a $100 million master mortgage loan with economic terms substantially similar to the master lease. The master lease, the master mortgage loan and the development agreements are all cross-defaulted and cross-collateralized.
A venture between an MPT affiliate and existing management of Ernest will acquire Ernest Health, Inc. for approximately $100 million, including approximately $96.5 million in MPT financing. MPT will have rights to a significant percentage of the profits and distributions of Ernest.
The Company intends to fund the acquisition with a combination of borrowings under MPT’s revolving credit facility, borrowings under a new term loan facility, as described below, net proceeds from other debt or equity capital market issuances, or a combination of the foregoing.
RBC Capital Markets, LLC acted as MPT’s exclusive financial advisor for this transaction.
PORTFOLIO UPDATE AND FUTURE OUTLOOK
Upon completion of this transaction, Medical Properties Trust’s portfolio metrics will approximate the following:
This estimate will change if, among other things, the Ernest transactions are not completed, the Company acquires additional assets, market interest rates change, debt is refinanced, new shares of common stock are issued, additional debt is incurred, assets are sold, the River Oaks property is leased, other operating expenses vary or existing leases do not perform in accordance with their terms. In addition, these estimates do not include the effects, if any, of real estate operating costs, litigation costs, debt refinancing costs, acquisition costs, new interest rate hedging activities, write-offs of straight-line rent or other non-recurring or unplanned transactions; nor do they include earnings, if any, from the Company’s profits interests or other investments in lessees.
“This is just the beginning of 2012 and there is still plenty of time left for making other investments this year,” Aldag concluded. “There are many other opportunities to invest with other strong hospital operators like Ernest Health, and we are enthused about the additional growth possibilities in 2012 and beyond.”
SENIOR CREDIT FACILITIES
In connection with announcement of the Ernest transactions, on January 31, 2012, the Company received a commitment letter and term sheet for an $80.0 million senior unsecured term loan facility from J.P. Morgan Chase Bank, N.A. and RBC Capital Markets, LLC. The term sheet provides for customary financial and operating covenants, substantially consistent with the Company’s existing revolving credit facility, including covenants relating to total leverage ratio, fixed charge coverage ratio, mortgage secured leverage ratio, recourse mortgage secured indebtedness, consolidated adjusted net worth, unsecured leverage ratio and interest coverage ratio, and covenants restricting the incurrence of debt, imposition of liens, the payment of dividends and entering into affiliate transactions. The term sheet also provides for customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations and failure to comply with our covenants.
The Company expects to close and fund the new term loan facility concurrently with the closing of the Ernest transactions. Effectiveness of the new term loan facility is subject to, among other things, definitive documentation and the satisfaction of customary closing conditions. The Company cannot guarantee that it will be able to successfully close the new term loan facility on the terms described herein or at all.
The Company’s existing revolving credit facility includes an accordion feature pursuant to which borrowings thereunder can be increased up to $400.0 million from $330.0 million. The Company requested a $70 million increase in its revolving credit facility contemporaneously with the closing of the new term loan facility. The Company expects that the administrative agent under the revolving credit facility will arrange a syndicate of lenders willing to hold the requested incremental revolving commitments but the Company cannot guarantee that commitments will be obtained for this incremental facility. The Company currently has $1.3 million outstanding under its revolving credit facility.
CONFERENCE CALL AND WEBCAST
The Company has scheduled a conference call and webcast on Tuesday, January 31, 2012 at 4:30 p.m. Eastern Time to present the Company’s financial and operating results for the quarter and year ended December 31, 2011 and to discuss this acquisition. The dial-in telephone numbers for the conference call are 800-573-4842 (U.S.) and 617-224-4327 (International); using passcode 18361530. The conference call will also be available via webcast in the Investor Relations’ section of the Company’s website, www.medicalpropertiestrust.com.
A telephone and webcast replay of the call will be available from shortly after the completion through February 14, 2012. Telephone numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode is 57805063.
About Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a Birmingham, Alabama based self-advised real estate investment trust formed to capitalize on the changing trends in healthcare delivery by acquiring and developing net-leased healthcare facilities. These facilities include inpatient rehabilitation hospitals, long-term acute care hospitals, regional acute care hospitals, ambulatory surgery centers and other single-discipline healthcare facilities, such as heart hospitals and orthopedic hospitals. For more information, please visit the Company’s website at www.medicalpropertiestrust.com.
The statements in this press release that are forward looking are based on current expectations and actual results or future events may differ materially. Words such as “expects,” “believes,” “anticipates,” “intends,” “will,” “should” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward-looking statements, including without limitation: the possibility that the Ernest transactions are not consummated; if consummated, new risks related to integrating the Ernest assets and business; the potential adverse consequences related to financing the Ernest acquisitions with debt; the capacity of the Company’s tenants to meet the terms of their agreements; annual Normalized FFO per share; the amount of acquisitions of healthcare real estate, if any; the repayment of debt arrangements; statements concerning the additional income to the Company as a result of ownership interests in certain hospital operations and the timing of such income; the restructuring of the Company’s investments in non-revenue producing properties; the payment of future dividends, if any; completion of additional debt arrangements; and additional investments; national and economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a REIT for federal income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or healthcare real estate in particular. For further discussion of the factors that could affect outcomes, please refer to the “Risk factors” section of the Company’s Form 10-K for the year ended December 31, 2010, as amended, and as updated by our subsequently filed Quarterly Reports on Form 10-Q and our other SEC filings. Except as otherwise required by the federal securities laws, the Company undertakes no obligation to update the information in this press release.\
http://tourism9.com/ http://vkins.com/
The corrected release reads:
MEDICAL PROPERTIES TRUST IN $400 MILLION TRANSACTION WITH ERNEST HEALTH, INC. TO ADD 16 HOSPITALS TO PORTFOLIO
FFO Accretion of 26%
Medical Properties Trust, Inc. (NYSE: MPW – News) today announced that it has agreed to a series of transactions with Ernest Health, Inc. that will add 16 existing post acute care hospitals to MPT’s investment portfolio for approximately $300 million. In addition, the Company will acquire a significant percentage of Ernest Health’s operations, in partnership with Ernest Health’s management team. This $400 million transaction increases Medical Properties Trust’s overall assets by 25 percent, to more than $2.0 billion.
Upon completion of the transactions, which is subject to regulatory and other customary conditions, MPT is expected to have investments in 78 hospital facilities in 24 states, total assets of approximately $2.0 billion and no tenant group that represents more than 20% of its total assets. The transactions are expected to add approximately $0.19 per share in funds from operations in the 12 months following the closing, which is anticipated to occur during the first quarter of 2012. Based on MPT’s most recently disclosed expectations of future FFO, the incremental FFO from the Ernest transactions will represent an increase of 26%.
Founded in 2003, Ernest Health, Inc. is one of the nation’s leading operators of long-term acute care hospitals (“LTACHs”) and inpatient rehabilitation hospitals (“IRFs”). Headquartered in Albuquerque, New Mexico, Ernest operates 16 properties (8 LTACHs and 8 IRFs) with 606 beds across nine states. Subsequent to the transactions, Ernest will be managed pursuant to agreements with current executive management, including Darby Brockette, Ernest’s Chief Executive Officer.
“We are delighted to welcome Ernest Health to the MPT family of premier healthcare facilities,” said Edward K Aldag, Jr., chairman, president and CEO of Medical Properties Trust, Inc. “We have known the Ernest management team for a long time and we have watched the company grow from its inception during the same year MPT was founded. We have been very impressed with Ernest’s growth and with the management team’s dedication to the delivery of high quality healthcare.” Aldag continued, “With transformative, highly accretive transactions like these, we continue to demonstrate our unique ability to create high quality long term sources of cash flow from hospital real estate. Completing these transactions will give MPT upside potential to the long term growth of Ernest, and adds another premiere post acute hospital operator to our relationships with others such as Vibra, Kindred, Healthsouth, LifeCare, Cornerstone and Post Acute.”
Among other benchmarks of quality, Aldag noted that Ernest Health’s inpatient rehabilitation facilities have been ranked among the top five percent of more than 800 IRFs in the United States – and that has held true of each Ernest rehabilitation hospital during each year of its operations. “This commitment to outstanding patient outcomes is only one of the many factors that make the acquisition of Ernest Health so attractive,” Aldag said.
Transaction Details
MPT will acquire the real estate assets of 12 Ernest facilities for an aggregate purchase price of $200 million, and lease the properties back to Ernest under a master lease structure with an initial term of 20 years and three five-year extension options. The real estate of four other Ernest facilities will serve as first lien collateral under a $100 million master mortgage loan with economic terms substantially similar to the master lease. The master lease, the master mortgage loan and the development agreements are all cross-defaulted and cross-collateralized.
A venture between an MPT affiliate and existing management of Ernest will acquire Ernest Health, Inc. for approximately $100 million, including approximately $96.5 million in MPT financing. MPT will have rights to a significant percentage of the profits and distributions of Ernest.
The Company intends to fund the acquisition with a combination of borrowings under MPT’s revolving credit facility, borrowings under a new term loan facility, as described below, net proceeds from other debt or equity capital market issuances, or a combination of the foregoing.
RBC Capital Markets, LLC acted as MPT’s exclusive financial advisor for this transaction.
PORTFOLIO UPDATE AND FUTURE OUTLOOK
Upon completion of this transaction, Medical Properties Trust’s portfolio metrics will approximate the following:
- Largest operator will comprise 20% of pro forma total assets;
- Assets in California will comprise 22% of pro forma total assets;
- MPT’s largest property will make up 4% of pro forma total assets;
- General acute care hospitals will comprise approximately 51% of total invested assets, LTACHs 27%, and IRFs 21%
This estimate will change if, among other things, the Ernest transactions are not completed, the Company acquires additional assets, market interest rates change, debt is refinanced, new shares of common stock are issued, additional debt is incurred, assets are sold, the River Oaks property is leased, other operating expenses vary or existing leases do not perform in accordance with their terms. In addition, these estimates do not include the effects, if any, of real estate operating costs, litigation costs, debt refinancing costs, acquisition costs, new interest rate hedging activities, write-offs of straight-line rent or other non-recurring or unplanned transactions; nor do they include earnings, if any, from the Company’s profits interests or other investments in lessees.
“This is just the beginning of 2012 and there is still plenty of time left for making other investments this year,” Aldag concluded. “There are many other opportunities to invest with other strong hospital operators like Ernest Health, and we are enthused about the additional growth possibilities in 2012 and beyond.”
SENIOR CREDIT FACILITIES
In connection with announcement of the Ernest transactions, on January 31, 2012, the Company received a commitment letter and term sheet for an $80.0 million senior unsecured term loan facility from J.P. Morgan Chase Bank, N.A. and RBC Capital Markets, LLC. The term sheet provides for customary financial and operating covenants, substantially consistent with the Company’s existing revolving credit facility, including covenants relating to total leverage ratio, fixed charge coverage ratio, mortgage secured leverage ratio, recourse mortgage secured indebtedness, consolidated adjusted net worth, unsecured leverage ratio and interest coverage ratio, and covenants restricting the incurrence of debt, imposition of liens, the payment of dividends and entering into affiliate transactions. The term sheet also provides for customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations and failure to comply with our covenants.
The Company expects to close and fund the new term loan facility concurrently with the closing of the Ernest transactions. Effectiveness of the new term loan facility is subject to, among other things, definitive documentation and the satisfaction of customary closing conditions. The Company cannot guarantee that it will be able to successfully close the new term loan facility on the terms described herein or at all.
The Company’s existing revolving credit facility includes an accordion feature pursuant to which borrowings thereunder can be increased up to $400.0 million from $330.0 million. The Company requested a $70 million increase in its revolving credit facility contemporaneously with the closing of the new term loan facility. The Company expects that the administrative agent under the revolving credit facility will arrange a syndicate of lenders willing to hold the requested incremental revolving commitments but the Company cannot guarantee that commitments will be obtained for this incremental facility. The Company currently has $1.3 million outstanding under its revolving credit facility.
CONFERENCE CALL AND WEBCAST
The Company has scheduled a conference call and webcast on Tuesday, January 31, 2012 at 4:30 p.m. Eastern Time to present the Company’s financial and operating results for the quarter and year ended December 31, 2011 and to discuss this acquisition. The dial-in telephone numbers for the conference call are 800-573-4842 (U.S.) and 617-224-4327 (International); using passcode 18361530. The conference call will also be available via webcast in the Investor Relations’ section of the Company’s website, www.medicalpropertiestrust.com.
A telephone and webcast replay of the call will be available from shortly after the completion through February 14, 2012. Telephone numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode is 57805063.
About Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a Birmingham, Alabama based self-advised real estate investment trust formed to capitalize on the changing trends in healthcare delivery by acquiring and developing net-leased healthcare facilities. These facilities include inpatient rehabilitation hospitals, long-term acute care hospitals, regional acute care hospitals, ambulatory surgery centers and other single-discipline healthcare facilities, such as heart hospitals and orthopedic hospitals. For more information, please visit the Company’s website at www.medicalpropertiestrust.com.
The statements in this press release that are forward looking are based on current expectations and actual results or future events may differ materially. Words such as “expects,” “believes,” “anticipates,” “intends,” “will,” “should” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward-looking statements, including without limitation: the possibility that the Ernest transactions are not consummated; if consummated, new risks related to integrating the Ernest assets and business; the potential adverse consequences related to financing the Ernest acquisitions with debt; the capacity of the Company’s tenants to meet the terms of their agreements; annual Normalized FFO per share; the amount of acquisitions of healthcare real estate, if any; the repayment of debt arrangements; statements concerning the additional income to the Company as a result of ownership interests in certain hospital operations and the timing of such income; the restructuring of the Company’s investments in non-revenue producing properties; the payment of future dividends, if any; completion of additional debt arrangements; and additional investments; national and economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a REIT for federal income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or healthcare real estate in particular. For further discussion of the factors that could affect outcomes, please refer to the “Risk factors” section of the Company’s Form 10-K for the year ended December 31, 2010, as amended, and as updated by our subsequently filed Quarterly Reports on Form 10-Q and our other SEC filings. Except as otherwise required by the federal securities laws, the Company undertakes no obligation to update the information in this press release.\
http://tourism9.com/ http://vkins.com/
2012年1月30日星期一
Venture Capital Investment in Europe Fell 14% in 2011
LONDON, Jan. 30, 2012 /PRNewswire/ – Venture capitalists put euro 4.4 billion into 1,012 deals for European companies in 2011, a 14% decline in investment and 19% decline in deal flow from 2010, according to Dow Jones VentureSource. This marks the lowest annual deal count for Europe since VentureSource began tracking the region in 2000.
The fourth quarter was the weakest of the year in terms of deal activity as 194 deals collected euro 1.1 billion, a 43% drop in deals and 38% decline in investment over the same period in 2010. Weakness in the fourth quarter is notable as it is traditionally one of the most active quarters for deals.
“Venture capitalists are having difficulty raising funds as the Euro crisis weighs on limited partners’ minds and fewer companies are finding exits. This has naturally led to a slowdown in investment. With less capital flowing into venture firms, there’s less to invest in start-ups,” said Anthony Sheldon, research manager, Dow Jones VentureSource. The median size of a European venture capital deal was euro 2 million in 2011, on par with 2010.
Exits Mirror Fourth-Quarter Drop in Investment
The fourth quarter’s weakness in investments mirrored the exit environment. The fourth quarter of 2011 was the year’s weakest for mergers and acquisitions (M&As) and initial public offerings (IPOs) as 30 European venture-backed companies were acquired and two companies went public.
In all of 2011, 148 companies exited via an M&A, raising euro 7 billion, a 12% decline in deals and 7% increase in capital raised. Companies that got acquired, however, recorded the highest median raised on record. The median paid for an acquisition in 2011 was euro 5.1 million.
In all of 2011, 14 venture-backed companies went public, raising euro 695 million, a drop in IPOs but an increase in capital raised from 2010 when 18 IPOs raised euro 438 million.
As VCs Focus on Web, Consumer Services Investment Passes IT for First Time Since 2001
For the first time since 2001, the Web-heavy Consumer Services industry raised more capital than the Information Technology (IT) industry. Consumer Services companies raised euro 1.1 billion for 223 deals in 2011, a 63% increase in investment despite a 6% drop in deals from 2010. It was the industry’s strongest year for investment since 2001. IT companies raised $812 million for 270 deals in 2011, a 50% decline in investment and 25% decline in deals.
More than half of the capital collected by the Consumer Services industry went to the social media, entertainment and shopping companies in the Consumer Information Services sector. Those companies raised euro 691 million for 192 deals, a 79% increase in investment despite an 8% decline in deals.
Within the IT industry, Software remained the most popular investment area, driven by interest in business applications software and communications software. The Software sector raised euro 467 million through 194 deals in 2011, a 14% decline in investment and 13% decline in deal activity.
Medical Devices Offers Some Stability in Healthcare
As deal activity and investment fell in all areas of Healthcare, the Medical Devices sector offered moderate stability, seeing a drop of just 7% in both deal activity and investment. Medical Devices companies raised euro 323 million for 91 deals in 2011, a mild decline from the euro 348 million raised for 98 deals in 2010.
As usual, Biopharmaceuticals took the lion’s share of the industry’s investment as 121 deals raised euro 856 million, a 29% decline in deals and 20% decline in investment.
Uptick in Deals for Advertising, Data Companies
The Business Support Services sector, which includes companies developing technologies and services for data management, advertising and marketing, was the only sector to see an uptick in both deals and investment in 2011. The sector raised euro 479 million for 90 deals, a 62% increase in investment and 5% increase in deals.
The broader Business and Financial Services industry, which includes the Business Support Services sector as well as financial services and engineering companies, raised euro 614 million for 132 deals, a 15% increase in capital invested despite a 12% decline in investment.
Companies Focused on Renewables Capture Most Energy Investment
In 2011, 56 deals in the Energy & Utilities industry raised euro 253 million, a 26% decline in deals and 25% decline in investment. Renewable Energy companies accounted for most of the industry’s investment, raising euro 238 million for 49 deals.
Country Perspectives
Europe’s four major countries for venture investment – the U.K., France, Germany and Sweden – witnessed record-low deal activity in 2011.
About Dow JonesDow Jones & Company is a global provider of news and business information and a developer of technology to deliver content to consumers and organizations across multiple platforms. Dow Jones produces newspapers, newswires, Web sites, apps, newsletters, magazines, proprietary databases, conferences, radio and video. Its premier brands include The Wall Street Journal, Dow Jones Newswires, Factiva, Barron’s, MarketWatch, SmartMoney and All Things D. Its information services combine technology with news and data to support business decision making. The company pioneered the first successful paid online news site and its industry leading innovation enables it to serve customers wherever they may be, via the Web, mobile devices and tablets. The Dow Jones Local Media Group publishes community newspapers, Web sites and other products in six U.S. states. Dow Jones & Company (www.dowjones.com) is a News Corporation company (NASDAQ: NWS, NWSA; ASX: NWS, NWSLV; http://www.newscorp.com/).
http://tourism9.com/ http://vkins.com/
The fourth quarter was the weakest of the year in terms of deal activity as 194 deals collected euro 1.1 billion, a 43% drop in deals and 38% decline in investment over the same period in 2010. Weakness in the fourth quarter is notable as it is traditionally one of the most active quarters for deals.
“Venture capitalists are having difficulty raising funds as the Euro crisis weighs on limited partners’ minds and fewer companies are finding exits. This has naturally led to a slowdown in investment. With less capital flowing into venture firms, there’s less to invest in start-ups,” said Anthony Sheldon, research manager, Dow Jones VentureSource. The median size of a European venture capital deal was euro 2 million in 2011, on par with 2010.
Exits Mirror Fourth-Quarter Drop in Investment
The fourth quarter’s weakness in investments mirrored the exit environment. The fourth quarter of 2011 was the year’s weakest for mergers and acquisitions (M&As) and initial public offerings (IPOs) as 30 European venture-backed companies were acquired and two companies went public.
In all of 2011, 148 companies exited via an M&A, raising euro 7 billion, a 12% decline in deals and 7% increase in capital raised. Companies that got acquired, however, recorded the highest median raised on record. The median paid for an acquisition in 2011 was euro 5.1 million.
In all of 2011, 14 venture-backed companies went public, raising euro 695 million, a drop in IPOs but an increase in capital raised from 2010 when 18 IPOs raised euro 438 million.
As VCs Focus on Web, Consumer Services Investment Passes IT for First Time Since 2001
For the first time since 2001, the Web-heavy Consumer Services industry raised more capital than the Information Technology (IT) industry. Consumer Services companies raised euro 1.1 billion for 223 deals in 2011, a 63% increase in investment despite a 6% drop in deals from 2010. It was the industry’s strongest year for investment since 2001. IT companies raised $812 million for 270 deals in 2011, a 50% decline in investment and 25% decline in deals.
More than half of the capital collected by the Consumer Services industry went to the social media, entertainment and shopping companies in the Consumer Information Services sector. Those companies raised euro 691 million for 192 deals, a 79% increase in investment despite an 8% decline in deals.
Within the IT industry, Software remained the most popular investment area, driven by interest in business applications software and communications software. The Software sector raised euro 467 million through 194 deals in 2011, a 14% decline in investment and 13% decline in deal activity.
Medical Devices Offers Some Stability in Healthcare
As deal activity and investment fell in all areas of Healthcare, the Medical Devices sector offered moderate stability, seeing a drop of just 7% in both deal activity and investment. Medical Devices companies raised euro 323 million for 91 deals in 2011, a mild decline from the euro 348 million raised for 98 deals in 2010.
As usual, Biopharmaceuticals took the lion’s share of the industry’s investment as 121 deals raised euro 856 million, a 29% decline in deals and 20% decline in investment.
Uptick in Deals for Advertising, Data Companies
The Business Support Services sector, which includes companies developing technologies and services for data management, advertising and marketing, was the only sector to see an uptick in both deals and investment in 2011. The sector raised euro 479 million for 90 deals, a 62% increase in investment and 5% increase in deals.
The broader Business and Financial Services industry, which includes the Business Support Services sector as well as financial services and engineering companies, raised euro 614 million for 132 deals, a 15% increase in capital invested despite a 12% decline in investment.
Companies Focused on Renewables Capture Most Energy Investment
In 2011, 56 deals in the Energy & Utilities industry raised euro 253 million, a 26% decline in deals and 25% decline in investment. Renewable Energy companies accounted for most of the industry’s investment, raising euro 238 million for 49 deals.
Country Perspectives
Europe’s four major countries for venture investment – the U.K., France, Germany and Sweden – witnessed record-low deal activity in 2011.
- The U.K. remained the favorite destination for venture capital investment in Europe in 2011. Companies in the U.K. raised euro 1.2 billion for 274 deals, a 36% decline in investment and 17% decline in deals.
- France came in second place as companies raised euro 728 million for 217 deals, a 15% decline in investment and 18% decline in deals.
- Germany came in third as companies raised euro 475 million for 120 deals, a 23% decline in investment and 26% decline in deals.
- Sweden came in fourth as companies raised euro 299 million for 67 deals, a 7% increase in investment despite a 36% decline in deals.
About Dow JonesDow Jones & Company is a global provider of news and business information and a developer of technology to deliver content to consumers and organizations across multiple platforms. Dow Jones produces newspapers, newswires, Web sites, apps, newsletters, magazines, proprietary databases, conferences, radio and video. Its premier brands include The Wall Street Journal, Dow Jones Newswires, Factiva, Barron’s, MarketWatch, SmartMoney and All Things D. Its information services combine technology with news and data to support business decision making. The company pioneered the first successful paid online news site and its industry leading innovation enables it to serve customers wherever they may be, via the Web, mobile devices and tablets. The Dow Jones Local Media Group publishes community newspapers, Web sites and other products in six U.S. states. Dow Jones & Company (www.dowjones.com) is a News Corporation company (NASDAQ: NWS, NWSA; ASX: NWS, NWSLV; http://www.newscorp.com/).
http://tourism9.com/ http://vkins.com/
2012年1月27日星期五
CN Creative Raises Series A Funding to Develop First Medically Approved Electronic Inhaler Nicotine Replacement …
MANCHESTER, England, Jan. 25, 2012 /PRNewswire/ — CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today announced it has raised a Series A financing round led by Advent Life Sciences. The financing raised 2 million pounds, equivalent to approximately US $3.1 million. CNC intends to use the investment to continue and finalise development of its Nicadex™ electronic inhaler nicotine replacement therapy (NRT) product for use as part of medically supervised smoking cessation programmes.
Despite large-scale public health efforts, about 20% of adults in the UK and the US continue to smoke. Smoking remains the most common cause of preventable death in the Western world and generates enormous costs for healthcare systems worldwide. Two-thirds of smokers report that they would like to quit, and about three-quarters of current smokers say they have tried to stop, but smoking is a powerfully addictive habit that can make quitting very difficult or almost impossible. Fewer than 10% of smokers are estimated to achieve success when trying to stop smoking on their own. In addition, studies show that currently available NRT products help only a small proportion of smokers to stop smoking permanently.
“CN Creative provides innovative approaches to reduce the harm caused by smoking, by helping smokers quit whenever possible or reduce their consumption of cigarettes when total abstinence is not achievable,” said David Newns, a co-founder and Company Director of CN Creative. “We believe our Nicadex electronic inhaler NRT, which will deliver pharmaceutical-grade nicotine using advanced electronic vaporisation technology, has the potential to help significant numbers of smokers stop entirely or significantly reduce their exposure to harmful tobacco smoke.”
Nicadex is similar in concept to the electronic cigarettes currently marketed to adult consumers by CN Creative and others, but with several key differences.
First, Nicadex will be tested in clinical trials and then submitted for regulatory review under the process used for other prescription NRT products, initially through the UK Medicines and Healthcare products Regulatory Agency (MHRA) and then through the US Food and Drug Administration (FDA) and other regulatory agencies.
Second, CNC intends to market the Nicadex electronic inhaler as a medically supervised NRT designed to reduce the harm caused by smoking and to help smokers quit as part of a comprehensive smoking cessation programme.
Third, the Nicadex electronic inhaler has been specially engineered and will be manufactured in the UK under the same stringent standards used for regulated medical products, and the pharmaceutical-grade nicotine solution it uses is being produced by CNC in its own UK-based cGMP facilities approved for the manufacture of prescription drugs.
“The support from our colleagues at Advent Life Sciences will enable CNC to undertake the clinical trials and medical regulatory review needed to confirm the safety and efficacy of Nicadex and to prepare for commercialisation. We expect to file for regulatory approval of the Nicadex electronic inhaler in the UK later this year,” added CN Creative co-founder and Company Director Chris Lord.
Nicadex is a hand-held device that delivers purified nicotine to the user through the vaporisation of a pharmaceutical-grade solution of nicotine. A rechargeable lithium battery powers the vaporiser that instantly turns the nicotine solution into a vapour that is inhaled by the user. Many users report that the sensation of using the Nicadex device is similar to smoking, but the vapour contains no smoke and none of the carbon monoxide, tar or thousands of toxic impurities that make smoking tobacco products so damaging to health. In addition, since there is no smoke, there are no smoke by-products that can cause “second-hand” harm to others.
“Decades of smoking cessation initiatives have had a positive impact on public health but millions continue to smoke and new approaches are urgently needed,” noted long-time smoking cessation and public health advocate Dr. Chris Steele. ”I am encouraged by the potential of the innovative Nicadex electronic inhaler being developed by CNC, which provides a smoke-free, tobacco-free nicotine replacement product in a format that is highly acceptable to smokers. If approved, Nicadex could be a valuable addition to our smoking cessation toolkit, immediately reducing the harm caused by smoking and enabling many smokers to proceed over time to full cessation. CNC’s emphasis on clinical testing, regulatory review, medical supervision and supportive services is encouraging, and I look forward to seeing the results of the clinical trials the company will be conducting this year.”
A distinctive element of CNC’s strategy is its recognition of the value of harm reduction. As noted in the influential 2010 UK government report, A Smokefree Future, “The tar and the carbon monoxide in smoked tobacco are the primary causes of smoking-related disease and death. … Nicotine (in the doses obtained from smoked and smokeless tobacco) is not a significant contributor to disease.” The report proposes that harm reduction measures should be an important element of smoking cessation programmes, noting that “this strategy … opens more routes to quitting, which, we believe, will help thousands more smokers to quit successfully. The new routes will encourage smokers to … manage their nicotine addiction using a safer alternative product … and dramatically reduce the harmful effects to their health, and the harmful effects to those around them. …”[1]
Similarly, after a comprehensive review of the medical and scientific literature, the American Association of Public Health Physicians (AAPHP) became the first medical organisation in the US officially to endorse tobacco harm reduction as a viable strategy to reduce the death toll related to cigarette smoking. It advocates in its white paper, The Case for Harm Reduction, that inveterate smokers – who are unable or unwilling to abstain from nicotine and tobacco – should be encouraged to switch to lower-risk smokeless tobacco products.[2]
Dale R. Pfost, PhD, a General Partner at Advent Life Sciences and the newly appointed Chairman of CN Creative commented, “CNC’s strategy of applying their smoking cessation expertise and the technology innovations first deployed in their Intellicig® electronic cigarettes to provide smokers with an advanced electronic inhaler nicotine replacement therapy is a potential game changer. We believe that Nicadex will significantly increase smokers’ chances of ending or reducing their reliance on smoking, while also reducing the well-documented health risks caused by smoking tobacco. With this investment in CN Creative, we aim to continue our track record of investing in innovative life science companies with the potential to become best-in-class in their fields.”
Kaasim Mahmood, a Partner at Advent Life Sciences who is joining the CN Creative Board of Directors, added, “We believe CNC’s products have great clinical and commercial potential, and we are delighted to provide the CNC team with financial and strategic support as they embark on the clinical studies and regulatory review process central to the success of this exciting new approach.”
[1] Department of Health (2010). A Smokefree Future, 2010. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111789.pdf.
[2] Nitzkin JL, Rodu B. Tobacco Control Task Force, American Association of Public Health Physicians. The Case for Harm Reduction for Control of Tobacco-related Illness and Death, 2008. Available at: http://www.aaphp.org/Resources/Documents/20081026HarmReductionResolutionAsPassedl.pdf
About CN Creative
Headquartered in the Bioscience Incubator at Manchester University in the UK, CN Creative provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. It has developed a distinctive portfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. CNC’s diverse products include QuitDirect, an NHS-accredited supplier of comprehensive smoking cessation services, the Intellicig® electronic cigarette, ECOpure proprietary high purity nicotine preparations and NRT Direct, which provides traditional nicotine replacement therapy products and patient support services to publicly and privately sponsored smoking cessation programmes. CNC’s Nicadex™ electronic inhaler nicotine replacement therapy product is in clinical development for use as part of medically supervised smoking cessation programmes. For more information, visit www.cncbio.co.uk.
About Advent Life Sciences
Advent Life Sciences is the dedicated Life Sciences Fund at Advent Venture Partners, one of Europe’s best-established growth and venture capital firms. Advent Life Sciences invests predominantly in early-stage and growth equity life sciences companies in the UK, Europe and the US. It will back companies that have a first- or best-in-class approach in a range of sectors within the life sciences, including new drug discovery, enabling technologies, med-tech and diagnostics.
The Advent Life Sciences team is a leader in European life sciences capital. Its investments include PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases acquired by Johnson & Johnson; EUSA Pharma, a rapidly growing transatlantic specialty pharmaceutical company focused on late-stage oncology, pain control and critical care products; and, Algeta (OSE: ALGETA.OL – News), an oncology company developing treatments for bone metastases and disseminated tumours. For more information see www.adventventures.com.
For more information, please contact:
CN CreativeMediaBarbara Lindheim or Jennifer Anderson, BioCom Partners:
blindheim@biocompartners.com, +1 212 584-2276 ext. 201
janderson@biocompartners.com, +1 212 584-2276 ext. 202
CorporateDavid Newns
david.newns@cncbio.com +44 (0) 7834 767 367
Advent Life SciencesSophie Kreifman, Grayling:
sophie.kreifman@grayling.com; +44 20 7592 7924
http://tourism9.com/ http://vkins.com/
Despite large-scale public health efforts, about 20% of adults in the UK and the US continue to smoke. Smoking remains the most common cause of preventable death in the Western world and generates enormous costs for healthcare systems worldwide. Two-thirds of smokers report that they would like to quit, and about three-quarters of current smokers say they have tried to stop, but smoking is a powerfully addictive habit that can make quitting very difficult or almost impossible. Fewer than 10% of smokers are estimated to achieve success when trying to stop smoking on their own. In addition, studies show that currently available NRT products help only a small proportion of smokers to stop smoking permanently.
“CN Creative provides innovative approaches to reduce the harm caused by smoking, by helping smokers quit whenever possible or reduce their consumption of cigarettes when total abstinence is not achievable,” said David Newns, a co-founder and Company Director of CN Creative. “We believe our Nicadex electronic inhaler NRT, which will deliver pharmaceutical-grade nicotine using advanced electronic vaporisation technology, has the potential to help significant numbers of smokers stop entirely or significantly reduce their exposure to harmful tobacco smoke.”
Nicadex is similar in concept to the electronic cigarettes currently marketed to adult consumers by CN Creative and others, but with several key differences.
First, Nicadex will be tested in clinical trials and then submitted for regulatory review under the process used for other prescription NRT products, initially through the UK Medicines and Healthcare products Regulatory Agency (MHRA) and then through the US Food and Drug Administration (FDA) and other regulatory agencies.
Second, CNC intends to market the Nicadex electronic inhaler as a medically supervised NRT designed to reduce the harm caused by smoking and to help smokers quit as part of a comprehensive smoking cessation programme.
Third, the Nicadex electronic inhaler has been specially engineered and will be manufactured in the UK under the same stringent standards used for regulated medical products, and the pharmaceutical-grade nicotine solution it uses is being produced by CNC in its own UK-based cGMP facilities approved for the manufacture of prescription drugs.
“The support from our colleagues at Advent Life Sciences will enable CNC to undertake the clinical trials and medical regulatory review needed to confirm the safety and efficacy of Nicadex and to prepare for commercialisation. We expect to file for regulatory approval of the Nicadex electronic inhaler in the UK later this year,” added CN Creative co-founder and Company Director Chris Lord.
Nicadex is a hand-held device that delivers purified nicotine to the user through the vaporisation of a pharmaceutical-grade solution of nicotine. A rechargeable lithium battery powers the vaporiser that instantly turns the nicotine solution into a vapour that is inhaled by the user. Many users report that the sensation of using the Nicadex device is similar to smoking, but the vapour contains no smoke and none of the carbon monoxide, tar or thousands of toxic impurities that make smoking tobacco products so damaging to health. In addition, since there is no smoke, there are no smoke by-products that can cause “second-hand” harm to others.
“Decades of smoking cessation initiatives have had a positive impact on public health but millions continue to smoke and new approaches are urgently needed,” noted long-time smoking cessation and public health advocate Dr. Chris Steele. ”I am encouraged by the potential of the innovative Nicadex electronic inhaler being developed by CNC, which provides a smoke-free, tobacco-free nicotine replacement product in a format that is highly acceptable to smokers. If approved, Nicadex could be a valuable addition to our smoking cessation toolkit, immediately reducing the harm caused by smoking and enabling many smokers to proceed over time to full cessation. CNC’s emphasis on clinical testing, regulatory review, medical supervision and supportive services is encouraging, and I look forward to seeing the results of the clinical trials the company will be conducting this year.”
A distinctive element of CNC’s strategy is its recognition of the value of harm reduction. As noted in the influential 2010 UK government report, A Smokefree Future, “The tar and the carbon monoxide in smoked tobacco are the primary causes of smoking-related disease and death. … Nicotine (in the doses obtained from smoked and smokeless tobacco) is not a significant contributor to disease.” The report proposes that harm reduction measures should be an important element of smoking cessation programmes, noting that “this strategy … opens more routes to quitting, which, we believe, will help thousands more smokers to quit successfully. The new routes will encourage smokers to … manage their nicotine addiction using a safer alternative product … and dramatically reduce the harmful effects to their health, and the harmful effects to those around them. …”[1]
Similarly, after a comprehensive review of the medical and scientific literature, the American Association of Public Health Physicians (AAPHP) became the first medical organisation in the US officially to endorse tobacco harm reduction as a viable strategy to reduce the death toll related to cigarette smoking. It advocates in its white paper, The Case for Harm Reduction, that inveterate smokers – who are unable or unwilling to abstain from nicotine and tobacco – should be encouraged to switch to lower-risk smokeless tobacco products.[2]
Dale R. Pfost, PhD, a General Partner at Advent Life Sciences and the newly appointed Chairman of CN Creative commented, “CNC’s strategy of applying their smoking cessation expertise and the technology innovations first deployed in their Intellicig® electronic cigarettes to provide smokers with an advanced electronic inhaler nicotine replacement therapy is a potential game changer. We believe that Nicadex will significantly increase smokers’ chances of ending or reducing their reliance on smoking, while also reducing the well-documented health risks caused by smoking tobacco. With this investment in CN Creative, we aim to continue our track record of investing in innovative life science companies with the potential to become best-in-class in their fields.”
Kaasim Mahmood, a Partner at Advent Life Sciences who is joining the CN Creative Board of Directors, added, “We believe CNC’s products have great clinical and commercial potential, and we are delighted to provide the CNC team with financial and strategic support as they embark on the clinical studies and regulatory review process central to the success of this exciting new approach.”
[1] Department of Health (2010). A Smokefree Future, 2010. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111789.pdf.
[2] Nitzkin JL, Rodu B. Tobacco Control Task Force, American Association of Public Health Physicians. The Case for Harm Reduction for Control of Tobacco-related Illness and Death, 2008. Available at: http://www.aaphp.org/Resources/Documents/20081026HarmReductionResolutionAsPassedl.pdf
About CN Creative
Headquartered in the Bioscience Incubator at Manchester University in the UK, CN Creative provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. It has developed a distinctive portfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. CNC’s diverse products include QuitDirect, an NHS-accredited supplier of comprehensive smoking cessation services, the Intellicig® electronic cigarette, ECOpure proprietary high purity nicotine preparations and NRT Direct, which provides traditional nicotine replacement therapy products and patient support services to publicly and privately sponsored smoking cessation programmes. CNC’s Nicadex™ electronic inhaler nicotine replacement therapy product is in clinical development for use as part of medically supervised smoking cessation programmes. For more information, visit www.cncbio.co.uk.
About Advent Life Sciences
Advent Life Sciences is the dedicated Life Sciences Fund at Advent Venture Partners, one of Europe’s best-established growth and venture capital firms. Advent Life Sciences invests predominantly in early-stage and growth equity life sciences companies in the UK, Europe and the US. It will back companies that have a first- or best-in-class approach in a range of sectors within the life sciences, including new drug discovery, enabling technologies, med-tech and diagnostics.
The Advent Life Sciences team is a leader in European life sciences capital. Its investments include PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases acquired by Johnson & Johnson; EUSA Pharma, a rapidly growing transatlantic specialty pharmaceutical company focused on late-stage oncology, pain control and critical care products; and, Algeta (OSE: ALGETA.OL – News), an oncology company developing treatments for bone metastases and disseminated tumours. For more information see www.adventventures.com.
For more information, please contact:
CN CreativeMediaBarbara Lindheim or Jennifer Anderson, BioCom Partners:
blindheim@biocompartners.com, +1 212 584-2276 ext. 201
janderson@biocompartners.com, +1 212 584-2276 ext. 202
CorporateDavid Newns
david.newns@cncbio.com +44 (0) 7834 767 367
Advent Life SciencesSophie Kreifman, Grayling:
sophie.kreifman@grayling.com; +44 20 7592 7924
http://tourism9.com/ http://vkins.com/
2012年1月20日星期五
U.S. Venture Investment Rose 10% in 2011, Despite Fourth Quarter Decline
NEW YORK, Jan. 20, 2012 /PRNewswire/ – Venture capital investment slowed in the fourth quarter of 2011 as investors put $7.4 billion into 803 deals for U.S.-based venture companies, a decline in both capital invested and deal activity from the third quarter, according to Dow Jones VentureSource. The decline, which mirrors a fourth-quarter drop in exit activity, is notable because the final quarter of the year is traditionally one of the most active for financings and exits.
In all of 2011, investors put $32.6 billion into 3,209 venture deals, a 10% increase in capital raised and 6% increase in deals from 2010.
“The fourth quarter may have seen a temporary slowdown as venture capitalists reset their expectations for the exit market and entrepreneurs adjusted their companies’ valuations to suit the current climate,” said Jessica Canning, global research director for Dow Jones VentureSource. “Overall in 2011, venture investment continued its steady post-recession ascent with notable strength in enterprise solutions.”
The median amount invested in a financing round rose 16% to $5 million in 2011.
Healthcare and IT Investment Steady
In 2011, $8.4 billion was invested in 738 deals for Healthcare companies, a mild change from the previous year when the industry collected $8.3 billion for 747 deals. Biopharmaceuticals remained the industry’s most active investment area with 302 deals raising $3.9 billion, a 6% drop in deals and flat investment. Medical Devices was a close second with 290 deals raising $3.3 billion, a 3% decline in deal activity and 27% increase in investment.
The Medical IT sector, which has been benefiting from interest in electronic health records, Web and mobile applications, and information management solutions, saw a 26% increase in deal activity and 22% increase in capital raised as companies in the sector collected $633 million for 86 deals in 2011.
Companies in the Information Technology industry raised $7.9 billion for 1,004 deals in 2011, a slight uptick from 2010 when 967 deals raised $7.7 billion. The Software sector continued to be the most active investment area and was the only IT sector that saw an increase in both deals and capital raised as 743 deals raised $4.6 billion in 2011.
Venture capitalists’ interest in the hardware and chip sectors is steadily dwindling as much of the innovation in these areas is now done by corporations. Deals in the Electronics and Computer Hardware sector fell 13% to 110 and deals for Semiconductors fell 33% to 50. The Electronics and Computer Hardware sector and the Semiconductors sector raised $1.5 billion and $598 million in 2011 respectively.
VCs Put $5.2 Billion into Consumer Web Companies
Large later-stage rounds raised by well-known Web companies, including Twitter, Zynga and LivingSocial, pushed investment in the Consumer Information Services industry to $5.2 billion for 452 deals during 2011, a 23% increase in capital collected and 14% increase in deal activity from the previous year.
While 72% of the capital raised for the sector went to later-stage deals, there was still strong interest in seed- and first-rounds, which accounted for 57% of the sector’s deals.
“Venture capitalists still have a strong appetite for early-stage Web start-ups, but more mature companies may be swallowing some of the available cash,” said Zoran Basich, editor of Dow Jones VentureWire. “As companies delay the process of entering the public markets during a difficult time for IPOs, the additional venture funding they need is leaving investors with less capital for new investments.”
The median amount invested in a first round for a Web start-up shrank 33% to $2 million, while the median for a later-stage round ballooned 43% to $10 million.
Investment in Enterprise Start-Ups Rises
Driven by interest in data management, marketing and advertising companies, investment in the Business and Financial Services industry rose for the third consecutive year. In 2011, 546 deals for companies developing enterprise technologies or services raised $5.1 billion, a 9% increase in deals and 36% increase in capital collected from 2010.
Uptick in Energy Deals
The Energy and Utilities industry raised $2.9 billion for 134 deals, as investment was flat but deal activity rose 14%. As usual, Renewable Energy companies claimed most of the industry’s investment, as 110 deals raised $2.7 billion.
Early-Stage Deals Increase
Seed- and first-rounds accounted for 43% of deals and 18% of capital invested during 2011, an uptick in deal activity from the previous year when early-stage rounds claimed 39% of deals and 19% of capital raised. Second rounds dropped slightly from 21% of deal activity in 2010 to 20% in 2011, while the proportion of capital garnered by these deals rose from 18% in 2010 to 20% in 2011. Later-stage deals accounted for 35% of the year’s deals and 60% of total capital raised, a shift from the same period last year when they accounted for 38% of deals and 61% of capital raised.
For information on Dow Jones VentureSource’s research methodology, visit http://bit.ly/VSFAQs. For general information about Dow Jones VentureSource, visit http://www.dowjones.com/privatemarkets?from=pr-privatemarkets.
About Dow Jones
Dow Jones & Company is a global provider of news and business information and a developer of technology to deliver content to consumers and organizations across multiple platforms. Dow Jones produces newspapers, newswires, Web sites, apps, newsletters, magazines, proprietary databases, conferences, radio and video. Its premier brands include The Wall Street Journal, Dow Jones Newswires, Factiva, Barron’s, MarketWatch, SmartMoney and All Things D. Its information services combine technology with news and data to support business decision making. The company pioneered the first successful paid online news site and its industry leading innovation enables it to serve customers wherever they may be, via the Web, mobile devices and tablets. The Dow Jones Local Media Group publishes community newspapers, Web sites and other products in six U.S. states. Dow Jones & Company (www.dowjones.com) is a News Corporation company (NASDAQ: NWS, NWSA; ASX: NWS, NWSLV; http://www.newscorp.com/).
http://tourism9.com/ http://vkins.com/
In all of 2011, investors put $32.6 billion into 3,209 venture deals, a 10% increase in capital raised and 6% increase in deals from 2010.
“The fourth quarter may have seen a temporary slowdown as venture capitalists reset their expectations for the exit market and entrepreneurs adjusted their companies’ valuations to suit the current climate,” said Jessica Canning, global research director for Dow Jones VentureSource. “Overall in 2011, venture investment continued its steady post-recession ascent with notable strength in enterprise solutions.”
The median amount invested in a financing round rose 16% to $5 million in 2011.
Healthcare and IT Investment Steady
In 2011, $8.4 billion was invested in 738 deals for Healthcare companies, a mild change from the previous year when the industry collected $8.3 billion for 747 deals. Biopharmaceuticals remained the industry’s most active investment area with 302 deals raising $3.9 billion, a 6% drop in deals and flat investment. Medical Devices was a close second with 290 deals raising $3.3 billion, a 3% decline in deal activity and 27% increase in investment.
The Medical IT sector, which has been benefiting from interest in electronic health records, Web and mobile applications, and information management solutions, saw a 26% increase in deal activity and 22% increase in capital raised as companies in the sector collected $633 million for 86 deals in 2011.
Companies in the Information Technology industry raised $7.9 billion for 1,004 deals in 2011, a slight uptick from 2010 when 967 deals raised $7.7 billion. The Software sector continued to be the most active investment area and was the only IT sector that saw an increase in both deals and capital raised as 743 deals raised $4.6 billion in 2011.
Venture capitalists’ interest in the hardware and chip sectors is steadily dwindling as much of the innovation in these areas is now done by corporations. Deals in the Electronics and Computer Hardware sector fell 13% to 110 and deals for Semiconductors fell 33% to 50. The Electronics and Computer Hardware sector and the Semiconductors sector raised $1.5 billion and $598 million in 2011 respectively.
VCs Put $5.2 Billion into Consumer Web Companies
Large later-stage rounds raised by well-known Web companies, including Twitter, Zynga and LivingSocial, pushed investment in the Consumer Information Services industry to $5.2 billion for 452 deals during 2011, a 23% increase in capital collected and 14% increase in deal activity from the previous year.
While 72% of the capital raised for the sector went to later-stage deals, there was still strong interest in seed- and first-rounds, which accounted for 57% of the sector’s deals.
“Venture capitalists still have a strong appetite for early-stage Web start-ups, but more mature companies may be swallowing some of the available cash,” said Zoran Basich, editor of Dow Jones VentureWire. “As companies delay the process of entering the public markets during a difficult time for IPOs, the additional venture funding they need is leaving investors with less capital for new investments.”
The median amount invested in a first round for a Web start-up shrank 33% to $2 million, while the median for a later-stage round ballooned 43% to $10 million.
Investment in Enterprise Start-Ups Rises
Driven by interest in data management, marketing and advertising companies, investment in the Business and Financial Services industry rose for the third consecutive year. In 2011, 546 deals for companies developing enterprise technologies or services raised $5.1 billion, a 9% increase in deals and 36% increase in capital collected from 2010.
Uptick in Energy Deals
The Energy and Utilities industry raised $2.9 billion for 134 deals, as investment was flat but deal activity rose 14%. As usual, Renewable Energy companies claimed most of the industry’s investment, as 110 deals raised $2.7 billion.
Early-Stage Deals Increase
Seed- and first-rounds accounted for 43% of deals and 18% of capital invested during 2011, an uptick in deal activity from the previous year when early-stage rounds claimed 39% of deals and 19% of capital raised. Second rounds dropped slightly from 21% of deal activity in 2010 to 20% in 2011, while the proportion of capital garnered by these deals rose from 18% in 2010 to 20% in 2011. Later-stage deals accounted for 35% of the year’s deals and 60% of total capital raised, a shift from the same period last year when they accounted for 38% of deals and 61% of capital raised.
For information on Dow Jones VentureSource’s research methodology, visit http://bit.ly/VSFAQs. For general information about Dow Jones VentureSource, visit http://www.dowjones.com/privatemarkets?from=pr-privatemarkets.
About Dow Jones
Dow Jones & Company is a global provider of news and business information and a developer of technology to deliver content to consumers and organizations across multiple platforms. Dow Jones produces newspapers, newswires, Web sites, apps, newsletters, magazines, proprietary databases, conferences, radio and video. Its premier brands include The Wall Street Journal, Dow Jones Newswires, Factiva, Barron’s, MarketWatch, SmartMoney and All Things D. Its information services combine technology with news and data to support business decision making. The company pioneered the first successful paid online news site and its industry leading innovation enables it to serve customers wherever they may be, via the Web, mobile devices and tablets. The Dow Jones Local Media Group publishes community newspapers, Web sites and other products in six U.S. states. Dow Jones & Company (www.dowjones.com) is a News Corporation company (NASDAQ: NWS, NWSA; ASX: NWS, NWSLV; http://www.newscorp.com/).
http://tourism9.com/ http://vkins.com/
2012年1月3日星期二
Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies …
NEW YORK , Jan. 3, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:
Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years
http://www.reportlinker.com/p0747902/Private-Equity-and-Venture-Capital-PE/VC-Activity-in-Medical-Devices—Number-of-Investments-in-Smaller-Companies-has-Increased-over-the-Past-Four-Years.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices
Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years
Summary
GBI Research’s report, “Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years” provides key data, information and analysis on the global medical devices market. The report provides private equity and venture capital (PE/VC) activity in 18 medical device market categories – In Vitro Diagnostics, Cardiovascular Devices, Orthopedic Devices, Anesthesia and Respiratory Devices, Dental Devices, Diabetes Care devices, Diagnostic Imaging, Drug Delivery Devices, Endoscopy Devices, Ear, Nose and Throat Devices, Healthcare IT, Hospital Supplies, Nephrology and Urology, Neurology Devices, Ophthalmic Devices, Patient Monitoring, Surgical Equipment and Wound Care Management. The report provides comprehensive information on the factors affecting PE/VC investment in these categories. The report also reviews the detailed analysis of the PE/VC deals worth greater than $100m in each category. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
- Key geographies covered include North America , Europe and the Asia-Pacific .
- PE/VC activity in the following market categories – In Vitro Diagnostics, Cardiovascular Devices, Orthopedic Devices, Anesthesia and Respiratory Devices, Dental Devices, Diabetes Care devices, Diagnostic Imaging, Drug Delivery Devices, Endoscopy Devices, ENT Devices, Healthcare IT, Hospital Supplies, Nephrology and Urology, Neurology Devices, Ophthalmic Devices, Patient Monitoring, Surgical Equipment and Wound Care Management
- PE/VC deals from 2007 to 2010 in the medical device market and detailed analysis of deals greater than $100m in size.
- The report also covers top financial advisors for the PE/VC deals from 2007 to 2010 in the medical device market.
Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the medical devices market globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit PE/VC opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.
- What’s the next big thing in the PE/VC activity in medical devices landscape? Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global medical devices market and the factors shaping it.
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 GBI Research Report Guidance 9
3 PE/VC Deals Summary in the Medical Device Industry 10
3.1 PE/VC Deals by Number and Deal Value, 2007–2010 10
3.2 Segmentation of PE/VC Deals by Stages, 2007–2010 11
3.2.1 Conclusion 12
3.3 Withdrawn/Terminated Deals 12
3.3.1 Ion Beam Applications Terminated Sale of Its BioAssays Unit 13
3.3.2 Smiths Group Rejects Cash Bid of Apax Partners for Smiths Medical 13
3.3.3 Ares Life Sciences, Essex , Intesa and Alpha Terminated Acquisition of Sorin 14
3.3.4 AMICAS Terminated Acquisition with Thoma Bravo 14
3.3.5 Q-Med Terminated Offer for Its Acquisition by Ivytan 15
3.3.6 Endologix Terminated Offer for Its Acquisition by Elliot Associates 15
3.3.7 Conclusion 16
4 PE/VC Deals in Medical Devices by Geography 17
4.1 PE/VC Deals in North America 17
4.2 PE/VC Deals in Europe 19
4.3 PE/VC Deals in the Asia-Pacific 21
4.3.1 Conclusion 22
5 PE/VC Activity in Medical Devices by Market 23
5.1 In Vitro Diagnostics 23
5.1.1 Deals Analysis 24
5.1.2 PE/VC Deals – In Vitro Diagnostics 24
5.1.3 Pacific Biosciences Secured Additional $59m in Series F Round of Financing 25
5.1.4 Legal & General Ventures Sells LGC to Bridgepoint 25
5.1.5 Welsh, Carson, Anderson & Stowe Acquired Spectrum Laboratory Network from Apax Partners 26
5.1.6 Bridgepoint Capital Acquired Terveystalo Healthcare 27
5.1.7 Duke Street Acquired Biomnis 27
5.1.8 The EQT V fund Acquired Dako Denmark 28
5.2 Cardiovascular Devices 29
5.2.1 Deal Analysis 30
5.2.2 Ares Life Sciences Acquired Stake in Esaote 30
5.2.3 Boston Scientific Sells Fluid Management and Venous Access Businesses To Avista Capital 31
5.2.4 Cardionet Secures $110m in Series E Financing 32
5.3 Orthopedic Devices 33
5.3.1 Deals Analysis 34
5.3.2 Small Bone Innovations Secured $108m in Series D Financing 36
5.3.3 Globus Medical Secures $110m Series E Financing 36
5.4 Anesthesia and Respiratory Devices 38
5.4.1 Deals Analysis 39
5.4.2 Water Street Healthcare Acquires Stake in CareCentrix from Gentiva Health 39
5.5 Dental Devices 40
5.5.1 Deals Analysis 41
5.5.2 TA Associates Acquired Stake in Amann Girrbach 41
5.5.3 Palamon Capital Partners Completes Acquisition of Associated Dental Partners 42
5.6 Diabetes Care Devices 43
5.6.1 Deals Analysis 44
5.6.2 The Blackstone Group Acquires Apria Healthcare 44
5.7 Diagnostic Imaging 45
5.7.1 Deals Analysis 46
5.7.2 Bridgepoint Capital Acquired Terveystalo Healthcare 46
5.7.3 Merrill Lynch and Ares Acquires Euromedic from Warburg Pincus 47
5.7.4 Avista Capital Partners Acquired Bristol-Myers Squibb Medical Imaging 48
5.7.5 Dubai International Capital Acquired Alliance Medical from Bridgepoint Capital 48
5.7.6 DeA Capital and Mediobanca Acquired 53% Majority Stake in Generale de Sante 49
5.8 Drug Delivery Devices 50
5.8.1 Deals Analysis 51
5.8.2 Warburg Pincus Acquired Lifecore Biomedical 51
5.9 Endoscopy Devices 52
5.9.1 Deals Analysis 53
5.9.2 TPG Capital Acquires Axcan Pharma 53
5.10 Ear, Nose and Throat (ENT) Devices 54
5.10.1 Deals Analysis 55
5.10.2 Technitrol Sells Medtech Component Business To Altor 55
5.11 Healthcare IT 56
5.11.1 Huntsman Gay Global Acquires 51% Stake in Sunquest Information from Vista Equity Partners 58
5.11.2 BC Partners and Silver Lake Acquires MultiPlan from the Carlyle Group and Welsh, Carson, Anderson & Stowe 58
5.11.3 OMERS Private Equity Completes Acquisition of Logibec Groupe Informatique 59
5.11.4 Francisco Partners Completes Acquisition Of Quadramed 60
5.11.5 ikaSystems Received Additional Investment From Essex Woodlands Health 61
5.11.6 Truveris Raises $3.8m in First Venture Financing Round 61
5.11.7 Glocal Healthcare Systems to Raise $3.25m in Venture Financing 62
5.11.8 Apax Partners, Bluecross Blueshield and Regence Group Acquired the TriZetto Group 62
5.11.9 Merrill Lynch and Ares Acquired Euromedic From Warburg Pincus 63
5.11.10 General Atlantic And Hellman & Friedman Acquires Remaining 48% Stake In Emdeon Business Services From HLTH 64
5.11.11 TA Associates Acquired Alere Medical 64
5.12 Hospital Supplies 66
5.12.1 Deals Analysis 67
5.12.2 The Blackstone Group Completes Acquisition of Polymer Group 67
5.12.3 EQT Partners Completed Acquisition of HTL-Strefa 68
5.12.4 Lehman Brothers Acquired Angelica 68
5.12.5 Tenet Healthcare Sells Its Majority Stake in Broadlane to TowerBrook Capital Partners 69
5.13 Nephrology and Urology Devices 70
5.13.1 Deals Analysis 71
5.13.2 Merrill Lynch and Ares Acquired Euromedic from Warburg Pincus 71
5.14 Neurology Devices 72
5.14.1 Deals Analysis 73
5.15 Ophthalmic Devices 73
5.15.1 3i Acquired Ultralase from Corporacion Dermoestetica 74
5.15.2 Warburg Pincus Acquired Bausch & Lomb 75
5.16 Patient Monitoring 76
5.16.1 Deals Analysis 77
5.16.2 TA Associates Acquired Alere Medical 77
5.17 Surgical Equipment 78
5.17.1 Deals Analysis 79
5.17.2 PerkinElmer Sells Illumination and Detection Solutions Business to Veritas Capital Fund Management 79
5.17.3 HLTH Sells Porex to Aurora Capital 80
5.18 Wound Care Management 81
5.18.2 Investor Acquired 34% Stake in Molnlycke Health Care 82
5.18.3 Nordic Capital Fund and Avista Capital Partners Acquire ConvaTec from Bristol-Myers Squibb 83
5.18.4 Investor and Morgan Stanley Completed Acquisition of Molnlycke Health Care from Apax Partners 84
6 Global Medical Devices, Top Financial Advisors 86
6.1 Top Financial Advisors, PE/VC Deals Medical Devices 86
7 PE/VC Activity in Medical Devices- Appendix 87
7.1 Acronyms 87
7.2 Research Methodology 88
7.2.1 Secondary Research 88
7.2.2 Primary Research 88
7.2.3 Models 89
7.2.4 Forecasts 89
7.2.5 Expert Panels 89
7.3 Contact Us 89
7.4 Disclaimer 90
7.5 Sources 90
List of Tables
1.1 List of Tables
Table 1: Medical Devices Market, Global, PE/VC, by Number of Deals and Deal Value, 2007-2010 10
Table 2: Medical Devices Industry, Global, PE/VC Deals, Number of Deals by Stages, 2007-2010 11
Table 3: Medical Devices Industry, Global, PE/VC Deals, Withdrawn/Terminated Deals, 2007–2010 12
Table 4: Medical Devices Industry, North America , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 17
Table 5: Medical Devices, Europe , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 19
Table 6: Medical Devices Industry, Asia-Pacific , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 21
Table 7: In Vitro Diagnostics Market, Global, PE/VC, by Number of Deals, 2007–2010 23
Table 8: In Vitro Diagnostics Market, Global, PE/VC, by Deal Value ($m), 2007–2010 23
Table 9: In Vitro Diagnostics, Global, PE/VC Deals, 2007–2010 24
Table 10: Cardiovascular Devices Market, Global, PE/VCs, by Number of Deals, 2007–2010 29
Table 11: Cardiovascular Devices Market, Global, PE/VCs, by Deal Value ($m), 2007–2010 29
Table 12: Cardiovascular Devices, Global, PE/VC, 2007-2010 30
Table 13: Orthopedic Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 33
Table 14: Orthopedic Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 33
Table 15: Orthopedics Devices Market, Global, PE/VC, 2007–2010 35
Table 16: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 38
Table 17: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 38
Table 18: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Volume, 2007–2010 39
Table 19: Dental Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 40
Table 20: Dental Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 40
Table 21: Dental Devices Market, Global, PE/VC, 2007–2010 41
Table 22: Diabetes Care Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 43
Table 23: Diabetes Care Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 43
Table 24: Diabetes Care Devices, Global, PE/VC, 2007–2010 44
Table 25: Diagnostic Imaging Market, Global, PE/VC, by Number of Deals, 2007–2010 45
Table 26: Diagnostic Imaging Market, Global, PE/VC, by Deal Value ($m), 2007–2010 45
Table 27: Diagnostic Imaging Market, Global, PE/VC, by Deal Value ($m), 2007–2010 46
Table 28: Drug Delivery Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 50
Table 29: Drug Delivery Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 50
Table 30: Drug Delivery Devices, Global, PE/VC, 2007–2010 51
Table 31: Endoscopy Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 52
Table 32: Endoscopy Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 52
Table 33: Endoscopy Devices Market, PE/VC, by Volume, Global, 2007–2010 53
Table 34: ENT Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 54
Table 35: ENT Devices Market, PE/VC, by Deal Value ($m), Global, 2007–2010 54
Table 36: ENT Devices Market, Global, PE/VC, by Deal Volume, 2007–2010 55
Table 37: Healthcare IT Market, Global, PE/VC, by Number of Deals, 2007–2010 56
Table 38: Healthcare IT Market, Global, PE/VC, by Deal Value ($m), 2007–2010 56
Table 39: Healthcare IT Market, Global, PE/VC, by Deal Volume, 2007-2010 57
Table 40: Hospital Supplies Market, Global, PE/VC, by Number of Deals, 2007–2010 66
Table 41: Hospital Supplies Market, Global, PE/VC, by Deal Value ($m), 2007–2010 66
Table 42: Hospital Supplies Market, Global, PE/VC, by Deal Volume, 2007–2010 67
Table 43: Nephrology and Urology Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 70
Table 44: Nephrology and Urology Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 70
Table 45: Nephrology and Urology Devices Market, Global, PE/VC, by Deal Volume, 2007–2010 71
Table 46: Neurology Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 72
Table 47: Neurology Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 72
Table 48: Ophthalmic Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 73
Table 49: Ophthalmic Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 74
Table 50: Ophthalmic Devices Market, Global, PE/VC, by Deal Volume 2007-2010 74
Table 51: Patient Monitoring Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 76
Table 52: Patient Monitoring Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 76
Table 53: Patient Monitoring Devices Market, Global, PE/VC, by Deal Volume, 2007–2010 77
Table 54: Surgical Equipment Market, Global, PE/VC, by Number of Deals, 2007–2010 78
Table 55: Surgical Equipment Market, Global, PE/VC, Deal Value ($m), 2007–2010 78
Table 56: Surgical Equipment Market, Global, PE/VC, 2007–2010 79
Table 57: Wound Care Management Market, Global, PE/VC, by Number of Deals, 2007–2010 81
Table 58: Wound Care Management Market, Global, PE/VC, by Deal Value ($m), 2007–2010 81
Table 59: Wound Care Management, Global, PE/VC Deals, 2007–2010 82
Table 60: Medical Devices, Top Legal Advisors, 2007–2010 86
List of Figures
1.2 List of Figures
Figure 1: Medical Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 10
Figure 2: Medical Devices Industry, Global, PE/VC Deals, Deals by Stages (%), 2007–2010 11
Figure 3: Medical Devices Industry, North America , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 17
Figure 4: Medical Devices Industry, Europe , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 19
Figure 5: Medical Devices Industry, Asia-Pacific , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 21
Figure 6: In Vitro Diagnostics Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 23
Figure 7: Cardiovascular Devices Market, Global, PE/VCs, by Number of Deals and Deal Value ($m), 2007–2010 29
Figure 8: Orthopedic Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 33
Figure 9: Orthopedic Devices, Global, Pipeline Products Summary, 2010 34
Figure 10: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 38
Figure 11: Dental Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 40
Figure 12: Diabetes Care Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 43
Figure 13: Diagnostic Imaging Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 45
Figure 14: Drug Delivery Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 50
Figure 15: Endoscopy Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 52
Figure 16: ENT Devices Market, PE/VC, Global, by Number of Deals and Deal Value ($m), 2007–2010 54
Figure 17: Healthcare IT Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 56
Figure 18: Hospital Supplies Market, PE/VC, Global, by Number of Deals and Deal Value ($m), 2007–2010 66
Figure 19: Nephrology and Urology Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 70
Figure 20: Neurology Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 72
Figure 21: Ophthalmic Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 73
Figure 22: Patient Monitoring Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 76
Figure 23: Surgical Equipment Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 78
Figure 24: Wound Care Management Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 81
Figure 25: Medical Devices, Global, PE/VC Deals, Top Financial Advisors, 2007–2010 86
Companies Mentioned
To order this report:
Medical Devices Industry: Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years
More Market Research Report
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
http://tourism9.com/
Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years
http://www.reportlinker.com/p0747902/Private-Equity-and-Venture-Capital-PE/VC-Activity-in-Medical-Devices—Number-of-Investments-in-Smaller-Companies-has-Increased-over-the-Past-Four-Years.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices
Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years
Summary
GBI Research’s report, “Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years” provides key data, information and analysis on the global medical devices market. The report provides private equity and venture capital (PE/VC) activity in 18 medical device market categories – In Vitro Diagnostics, Cardiovascular Devices, Orthopedic Devices, Anesthesia and Respiratory Devices, Dental Devices, Diabetes Care devices, Diagnostic Imaging, Drug Delivery Devices, Endoscopy Devices, Ear, Nose and Throat Devices, Healthcare IT, Hospital Supplies, Nephrology and Urology, Neurology Devices, Ophthalmic Devices, Patient Monitoring, Surgical Equipment and Wound Care Management. The report provides comprehensive information on the factors affecting PE/VC investment in these categories. The report also reviews the detailed analysis of the PE/VC deals worth greater than $100m in each category. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
- Key geographies covered include North America , Europe and the Asia-Pacific .
- PE/VC activity in the following market categories – In Vitro Diagnostics, Cardiovascular Devices, Orthopedic Devices, Anesthesia and Respiratory Devices, Dental Devices, Diabetes Care devices, Diagnostic Imaging, Drug Delivery Devices, Endoscopy Devices, ENT Devices, Healthcare IT, Hospital Supplies, Nephrology and Urology, Neurology Devices, Ophthalmic Devices, Patient Monitoring, Surgical Equipment and Wound Care Management
- PE/VC deals from 2007 to 2010 in the medical device market and detailed analysis of deals greater than $100m in size.
- The report also covers top financial advisors for the PE/VC deals from 2007 to 2010 in the medical device market.
Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the medical devices market globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit PE/VC opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.
- What’s the next big thing in the PE/VC activity in medical devices landscape? Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global medical devices market and the factors shaping it.
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 GBI Research Report Guidance 9
3 PE/VC Deals Summary in the Medical Device Industry 10
3.1 PE/VC Deals by Number and Deal Value, 2007–2010 10
3.2 Segmentation of PE/VC Deals by Stages, 2007–2010 11
3.2.1 Conclusion 12
3.3 Withdrawn/Terminated Deals 12
3.3.1 Ion Beam Applications Terminated Sale of Its BioAssays Unit 13
3.3.2 Smiths Group Rejects Cash Bid of Apax Partners for Smiths Medical 13
3.3.3 Ares Life Sciences, Essex , Intesa and Alpha Terminated Acquisition of Sorin 14
3.3.4 AMICAS Terminated Acquisition with Thoma Bravo 14
3.3.5 Q-Med Terminated Offer for Its Acquisition by Ivytan 15
3.3.6 Endologix Terminated Offer for Its Acquisition by Elliot Associates 15
3.3.7 Conclusion 16
4 PE/VC Deals in Medical Devices by Geography 17
4.1 PE/VC Deals in North America 17
4.2 PE/VC Deals in Europe 19
4.3 PE/VC Deals in the Asia-Pacific 21
4.3.1 Conclusion 22
5 PE/VC Activity in Medical Devices by Market 23
5.1 In Vitro Diagnostics 23
5.1.1 Deals Analysis 24
5.1.2 PE/VC Deals – In Vitro Diagnostics 24
5.1.3 Pacific Biosciences Secured Additional $59m in Series F Round of Financing 25
5.1.4 Legal & General Ventures Sells LGC to Bridgepoint 25
5.1.5 Welsh, Carson, Anderson & Stowe Acquired Spectrum Laboratory Network from Apax Partners 26
5.1.6 Bridgepoint Capital Acquired Terveystalo Healthcare 27
5.1.7 Duke Street Acquired Biomnis 27
5.1.8 The EQT V fund Acquired Dako Denmark 28
5.2 Cardiovascular Devices 29
5.2.1 Deal Analysis 30
5.2.2 Ares Life Sciences Acquired Stake in Esaote 30
5.2.3 Boston Scientific Sells Fluid Management and Venous Access Businesses To Avista Capital 31
5.2.4 Cardionet Secures $110m in Series E Financing 32
5.3 Orthopedic Devices 33
5.3.1 Deals Analysis 34
5.3.2 Small Bone Innovations Secured $108m in Series D Financing 36
5.3.3 Globus Medical Secures $110m Series E Financing 36
5.4 Anesthesia and Respiratory Devices 38
5.4.1 Deals Analysis 39
5.4.2 Water Street Healthcare Acquires Stake in CareCentrix from Gentiva Health 39
5.5 Dental Devices 40
5.5.1 Deals Analysis 41
5.5.2 TA Associates Acquired Stake in Amann Girrbach 41
5.5.3 Palamon Capital Partners Completes Acquisition of Associated Dental Partners 42
5.6 Diabetes Care Devices 43
5.6.1 Deals Analysis 44
5.6.2 The Blackstone Group Acquires Apria Healthcare 44
5.7 Diagnostic Imaging 45
5.7.1 Deals Analysis 46
5.7.2 Bridgepoint Capital Acquired Terveystalo Healthcare 46
5.7.3 Merrill Lynch and Ares Acquires Euromedic from Warburg Pincus 47
5.7.4 Avista Capital Partners Acquired Bristol-Myers Squibb Medical Imaging 48
5.7.5 Dubai International Capital Acquired Alliance Medical from Bridgepoint Capital 48
5.7.6 DeA Capital and Mediobanca Acquired 53% Majority Stake in Generale de Sante 49
5.8 Drug Delivery Devices 50
5.8.1 Deals Analysis 51
5.8.2 Warburg Pincus Acquired Lifecore Biomedical 51
5.9 Endoscopy Devices 52
5.9.1 Deals Analysis 53
5.9.2 TPG Capital Acquires Axcan Pharma 53
5.10 Ear, Nose and Throat (ENT) Devices 54
5.10.1 Deals Analysis 55
5.10.2 Technitrol Sells Medtech Component Business To Altor 55
5.11 Healthcare IT 56
5.11.1 Huntsman Gay Global Acquires 51% Stake in Sunquest Information from Vista Equity Partners 58
5.11.2 BC Partners and Silver Lake Acquires MultiPlan from the Carlyle Group and Welsh, Carson, Anderson & Stowe 58
5.11.3 OMERS Private Equity Completes Acquisition of Logibec Groupe Informatique 59
5.11.4 Francisco Partners Completes Acquisition Of Quadramed 60
5.11.5 ikaSystems Received Additional Investment From Essex Woodlands Health 61
5.11.6 Truveris Raises $3.8m in First Venture Financing Round 61
5.11.7 Glocal Healthcare Systems to Raise $3.25m in Venture Financing 62
5.11.8 Apax Partners, Bluecross Blueshield and Regence Group Acquired the TriZetto Group 62
5.11.9 Merrill Lynch and Ares Acquired Euromedic From Warburg Pincus 63
5.11.10 General Atlantic And Hellman & Friedman Acquires Remaining 48% Stake In Emdeon Business Services From HLTH 64
5.11.11 TA Associates Acquired Alere Medical 64
5.12 Hospital Supplies 66
5.12.1 Deals Analysis 67
5.12.2 The Blackstone Group Completes Acquisition of Polymer Group 67
5.12.3 EQT Partners Completed Acquisition of HTL-Strefa 68
5.12.4 Lehman Brothers Acquired Angelica 68
5.12.5 Tenet Healthcare Sells Its Majority Stake in Broadlane to TowerBrook Capital Partners 69
5.13 Nephrology and Urology Devices 70
5.13.1 Deals Analysis 71
5.13.2 Merrill Lynch and Ares Acquired Euromedic from Warburg Pincus 71
5.14 Neurology Devices 72
5.14.1 Deals Analysis 73
5.15 Ophthalmic Devices 73
5.15.1 3i Acquired Ultralase from Corporacion Dermoestetica 74
5.15.2 Warburg Pincus Acquired Bausch & Lomb 75
5.16 Patient Monitoring 76
5.16.1 Deals Analysis 77
5.16.2 TA Associates Acquired Alere Medical 77
5.17 Surgical Equipment 78
5.17.1 Deals Analysis 79
5.17.2 PerkinElmer Sells Illumination and Detection Solutions Business to Veritas Capital Fund Management 79
5.17.3 HLTH Sells Porex to Aurora Capital 80
5.18 Wound Care Management 81
5.18.2 Investor Acquired 34% Stake in Molnlycke Health Care 82
5.18.3 Nordic Capital Fund and Avista Capital Partners Acquire ConvaTec from Bristol-Myers Squibb 83
5.18.4 Investor and Morgan Stanley Completed Acquisition of Molnlycke Health Care from Apax Partners 84
6 Global Medical Devices, Top Financial Advisors 86
6.1 Top Financial Advisors, PE/VC Deals Medical Devices 86
7 PE/VC Activity in Medical Devices- Appendix 87
7.1 Acronyms 87
7.2 Research Methodology 88
7.2.1 Secondary Research 88
7.2.2 Primary Research 88
7.2.3 Models 89
7.2.4 Forecasts 89
7.2.5 Expert Panels 89
7.3 Contact Us 89
7.4 Disclaimer 90
7.5 Sources 90
List of Tables
1.1 List of Tables
Table 1: Medical Devices Market, Global, PE/VC, by Number of Deals and Deal Value, 2007-2010 10
Table 2: Medical Devices Industry, Global, PE/VC Deals, Number of Deals by Stages, 2007-2010 11
Table 3: Medical Devices Industry, Global, PE/VC Deals, Withdrawn/Terminated Deals, 2007–2010 12
Table 4: Medical Devices Industry, North America , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 17
Table 5: Medical Devices, Europe , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 19
Table 6: Medical Devices Industry, Asia-Pacific , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 21
Table 7: In Vitro Diagnostics Market, Global, PE/VC, by Number of Deals, 2007–2010 23
Table 8: In Vitro Diagnostics Market, Global, PE/VC, by Deal Value ($m), 2007–2010 23
Table 9: In Vitro Diagnostics, Global, PE/VC Deals, 2007–2010 24
Table 10: Cardiovascular Devices Market, Global, PE/VCs, by Number of Deals, 2007–2010 29
Table 11: Cardiovascular Devices Market, Global, PE/VCs, by Deal Value ($m), 2007–2010 29
Table 12: Cardiovascular Devices, Global, PE/VC, 2007-2010 30
Table 13: Orthopedic Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 33
Table 14: Orthopedic Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 33
Table 15: Orthopedics Devices Market, Global, PE/VC, 2007–2010 35
Table 16: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 38
Table 17: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 38
Table 18: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Volume, 2007–2010 39
Table 19: Dental Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 40
Table 20: Dental Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 40
Table 21: Dental Devices Market, Global, PE/VC, 2007–2010 41
Table 22: Diabetes Care Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 43
Table 23: Diabetes Care Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 43
Table 24: Diabetes Care Devices, Global, PE/VC, 2007–2010 44
Table 25: Diagnostic Imaging Market, Global, PE/VC, by Number of Deals, 2007–2010 45
Table 26: Diagnostic Imaging Market, Global, PE/VC, by Deal Value ($m), 2007–2010 45
Table 27: Diagnostic Imaging Market, Global, PE/VC, by Deal Value ($m), 2007–2010 46
Table 28: Drug Delivery Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 50
Table 29: Drug Delivery Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 50
Table 30: Drug Delivery Devices, Global, PE/VC, 2007–2010 51
Table 31: Endoscopy Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 52
Table 32: Endoscopy Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 52
Table 33: Endoscopy Devices Market, PE/VC, by Volume, Global, 2007–2010 53
Table 34: ENT Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 54
Table 35: ENT Devices Market, PE/VC, by Deal Value ($m), Global, 2007–2010 54
Table 36: ENT Devices Market, Global, PE/VC, by Deal Volume, 2007–2010 55
Table 37: Healthcare IT Market, Global, PE/VC, by Number of Deals, 2007–2010 56
Table 38: Healthcare IT Market, Global, PE/VC, by Deal Value ($m), 2007–2010 56
Table 39: Healthcare IT Market, Global, PE/VC, by Deal Volume, 2007-2010 57
Table 40: Hospital Supplies Market, Global, PE/VC, by Number of Deals, 2007–2010 66
Table 41: Hospital Supplies Market, Global, PE/VC, by Deal Value ($m), 2007–2010 66
Table 42: Hospital Supplies Market, Global, PE/VC, by Deal Volume, 2007–2010 67
Table 43: Nephrology and Urology Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 70
Table 44: Nephrology and Urology Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 70
Table 45: Nephrology and Urology Devices Market, Global, PE/VC, by Deal Volume, 2007–2010 71
Table 46: Neurology Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 72
Table 47: Neurology Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 72
Table 48: Ophthalmic Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 73
Table 49: Ophthalmic Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 74
Table 50: Ophthalmic Devices Market, Global, PE/VC, by Deal Volume 2007-2010 74
Table 51: Patient Monitoring Devices Market, Global, PE/VC, by Number of Deals, 2007–2010 76
Table 52: Patient Monitoring Devices Market, Global, PE/VC, by Deal Value ($m), 2007–2010 76
Table 53: Patient Monitoring Devices Market, Global, PE/VC, by Deal Volume, 2007–2010 77
Table 54: Surgical Equipment Market, Global, PE/VC, by Number of Deals, 2007–2010 78
Table 55: Surgical Equipment Market, Global, PE/VC, Deal Value ($m), 2007–2010 78
Table 56: Surgical Equipment Market, Global, PE/VC, 2007–2010 79
Table 57: Wound Care Management Market, Global, PE/VC, by Number of Deals, 2007–2010 81
Table 58: Wound Care Management Market, Global, PE/VC, by Deal Value ($m), 2007–2010 81
Table 59: Wound Care Management, Global, PE/VC Deals, 2007–2010 82
Table 60: Medical Devices, Top Legal Advisors, 2007–2010 86
List of Figures
1.2 List of Figures
Figure 1: Medical Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 10
Figure 2: Medical Devices Industry, Global, PE/VC Deals, Deals by Stages (%), 2007–2010 11
Figure 3: Medical Devices Industry, North America , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 17
Figure 4: Medical Devices Industry, Europe , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 19
Figure 5: Medical Devices Industry, Asia-Pacific , PE/VC Deals, by Deal Volume and Deal Value ($m), 2007–2010 21
Figure 6: In Vitro Diagnostics Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 23
Figure 7: Cardiovascular Devices Market, Global, PE/VCs, by Number of Deals and Deal Value ($m), 2007–2010 29
Figure 8: Orthopedic Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 33
Figure 9: Orthopedic Devices, Global, Pipeline Products Summary, 2010 34
Figure 10: Anesthesia and Respiratory Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 38
Figure 11: Dental Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 40
Figure 12: Diabetes Care Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 43
Figure 13: Diagnostic Imaging Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 45
Figure 14: Drug Delivery Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 50
Figure 15: Endoscopy Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 52
Figure 16: ENT Devices Market, PE/VC, Global, by Number of Deals and Deal Value ($m), 2007–2010 54
Figure 17: Healthcare IT Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 56
Figure 18: Hospital Supplies Market, PE/VC, Global, by Number of Deals and Deal Value ($m), 2007–2010 66
Figure 19: Nephrology and Urology Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 70
Figure 20: Neurology Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 72
Figure 21: Ophthalmic Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 73
Figure 22: Patient Monitoring Devices Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 76
Figure 23: Surgical Equipment Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 78
Figure 24: Wound Care Management Market, Global, PE/VC, by Number of Deals and Deal Value ($m), 2007–2010 81
Figure 25: Medical Devices, Global, PE/VC Deals, Top Financial Advisors, 2007–2010 86
Companies Mentioned
To order this report:
Medical Devices Industry: Private Equity and Venture Capital (PE/VC) Activity in Medical Devices – Number of Investments in Smaller Companies has Increased over the Past Four Years
More Market Research Report
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
http://tourism9.com/
2012年1月2日星期一
Student designer secures investment for iPhone app Summly
Summary: The Summly application could become the next must-have for students. Its teenage creator has secured a large investment for future development.
British teenager Nick D’Aloisio, designer of the ‘Summly’ app, has secured investment with a Hong-Kong based company.
Summly is an iPhone application that summarises and simplifies the content of web pages. Advertised as ‘a simple way to browse the web’, the 16-year old found inspiration for the app while studying for a history exam.
D’Aloisio found the current search options available online as inefficient, and this provoked the idea for the iPhone app. The developer said:
Before founding Summly, the teenage developer created Facemood, a service which used algorithms to determine the mood of Facebook users, and SongStumblr, a geosocial music discovery service.
(Source: Summly)
Summly has currently been optimised for 11 languages, and boasts 30,000 downloads since its release in mid-December. There are plans to tweak the app to become suitable for Android models early next year, as well as development of an online web version.
As an application for university or college students, this could be the future way to find and process information for studies quickly and effectively.
Although tools like Google give us access to incredible amounts of information instantaneously, it can be difficult to find suitable material — or extremely easy to become distracted.
By using Summly, it offers a new way to quickly scan summarised text and decide if that is the content you need to pursue. For those among us who leave revision until the last minute or pull an all-nighter finishing the essay due the next day, it could become one of the must-have applications you keep on your smartphone dashboard.
I’ll be looking forward to the Android release.
Summly is an iPhone application that summarises and simplifies the content of web pages. Advertised as ‘a simple way to browse the web’, the 16-year old found inspiration for the app while studying for a history exam.
D’Aloisio found the current search options available online as inefficient, and this provoked the idea for the iPhone app. The developer said:
“I thought that what I needed was a way of simplifying and summarising these web searches. Google has Instant Preview but that is just an image of the page. What I wanted was a content preview.”Li Ka-Shing, of Horizons Ventures, is the Chinese billionaire who ranks as one of the wealthiest people in the world. He has invested $250,000 (£159,000) in to the Summly project. Previous investments have included Facebook, Spotify and Skype.
Before founding Summly, the teenage developer created Facemood, a service which used algorithms to determine the mood of Facebook users, and SongStumblr, a geosocial music discovery service.
(Source: Summly)
Summly has currently been optimised for 11 languages, and boasts 30,000 downloads since its release in mid-December. There are plans to tweak the app to become suitable for Android models early next year, as well as development of an online web version.
As an application for university or college students, this could be the future way to find and process information for studies quickly and effectively.
Although tools like Google give us access to incredible amounts of information instantaneously, it can be difficult to find suitable material — or extremely easy to become distracted.
By using Summly, it offers a new way to quickly scan summarised text and decide if that is the content you need to pursue. For those among us who leave revision until the last minute or pull an all-nighter finishing the essay due the next day, it could become one of the must-have applications you keep on your smartphone dashboard.
I’ll be looking forward to the Android release.
London-based medical anthropologist Charlie Osborne is a journalist, graphic designer and former teacher.
Biography
Charlie Osborne
Charlie Osborne, Medical Anthropologist who studied at the University of Kent, UK, is a journalist, graphic designer and former teacher.
After studying Anthropology at university, she spent several years travelling and working across Europe and the Middle East, living for periods of time in Italy and Spain. She has been involved in the running of several businesses ranging from University media and events to b2b sales, and works currently as a freelance website designer and mobile development specialist.
She has particular interests in social media, intellectual property law, data protection and online hacker organisations.
http://tourism9.com/
After studying Anthropology at university, she spent several years travelling and working across Europe and the Middle East, living for periods of time in Italy and Spain. She has been involved in the running of several businesses ranging from University media and events to b2b sales, and works currently as a freelance website designer and mobile development specialist.
She has particular interests in social media, intellectual property law, data protection and online hacker organisations.
http://tourism9.com/
订阅：
博文 (Atom)